Sun Aiwen, Chen Hui, Shi Xiaojuan, Shang Zhanmin, Zhang Jishun
Clinical Laboratory, The Affiliated Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Department of Gastroenterology, The Affiliated Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Am Surg. 2025 Apr;91(4):570-578. doi: 10.1177/00031348241307397. Epub 2024 Dec 12.
ObjectiveTo assess the diagnostic value of joint detection of serum TK1, TSGF, CA199, and CA724 for gastric cancer and its relationship with clinicopathologic features and prognosis.MethodsThe 105 gastric cancer patients were enrolled. The diagnostic value of serum TK1, TSGF, CA199, and CA724 for gastric cancer and the relationship between these indicators and the clinicopathologic characteristics of gastric cancer patients were evaluated. During the follow-up period, recurrence, metastasis, and death were considered as poor prognosis. The relationships between serum TK1, TSGF, CA199, and CA724 levels and poor prognosis and factors affecting the poor prognosis of gastric cancer patients were analyzed.ResultsTK1, TSGF, CA199, and CA724 levels in the gastric cancer group were higher; serum TK1, TSGF, CA199, and CA724 levels were higher in gastric cancer patients with tumor diameters ≥3 cm, TNM stages III and IV, low/moderate degree of differentiation, infiltration depths of the muscular or plasma layer, and lymphatic metastases; AUC of combined TK1, TSGF, CA199, and CA724 (0.894) was higher than that of the four indicators alone; the percentage of gastric cancer patients with poor prognosis in patients with low serum TK1, TSGF, CA199, and CA724 levels was lower; serum TK1, TSGF, CA199, and CA724 levels were factors influencing poor prognosis of gastric cancer patients (all < 0.05).ConclusionElevated serum levels of TK1, TSGF, CA199, and CA724 are associated with clinicopathologic features and poor prognosis of gastric cancer and may be used as serum biomarkers for prognostic evaluation of gastric cancer patients.
评估血清胸苷激酶1（TK1）、肿瘤特异性生长因子（TSGF）、糖类抗原199（CA199）和糖类抗原724（CA724）联合检测对胃癌的诊断价值及其与临床病理特征和预后的关系。
纳入105例胃癌患者。评估血清TK1、TSGF、CA199和CA724对胃癌的诊断价值以及这些指标与胃癌患者临床病理特征的关系。随访期间，复发、转移和死亡被视为预后不良。分析血清TK1、TSGF、CA199和CA724水平与预后不良的关系以及影响胃癌患者预后不良的因素。
胃癌组TK1、TSGF、CA199和CA724水平较高；肿瘤直径≥3 cm、TNM分期为III和IV期、低/中度分化、肌层或浆膜层浸润深度以及有淋巴结转移的胃癌患者血清TK1、TSGF、CA199和CA724水平较高；TK1、TSGF、CA199和CA724联合检测的曲线下面积（AUC，0.894）高于单独检测这四项指标；血清TK1、TSGF、CA199和CA724水平较低的患者中预后不良的胃癌患者比例较低；血清TK1、TSGF、CA199和CA724水平是影响胃癌患者预后不良的因素（均P<0.05）。
血清TK1、TSGF、CA199和CA724水平升高与胃癌的临床病理特征和预后不良相关，可作为胃癌患者预后评估的血清生物标志物。
